From wikipedia...
GW501516 (also known as GW-501,516, [ 2] GW1516, GSK-516 and Endurobol[ 2]) is a) is a PPARδ receptor agonist that was previously nvestigated for drug use by GlaxoSmithKline. The drug was discovered to cause cancer in rats and GlaxoSmithKline[ 3][ 4] has ceased development.[ 3][ 4] It activates has ceased development It activates the same pathways activated through exercise, including PPARδ and AMP- activated protein kinase. It had been nvestigated as a potential treatment for obesity, diabetes, dyslipidemia and[ 5][ 6] cardiovascular disease.[ 5][ 6] GW501516 has GW501516 has a synergistic effect when combined with AICAR: the combination has been shown to significantly increase exercise endurance in animal studies more than either compound[ 7] alone.[ 7] alone.